Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets

Kim, In-Jeong; Lanthier, Paula A.; Clark, Madeline J.; Barrera, Rafael A. De La; Tighe, Michael; Szaba, Frank M.; Travis, Kelsey L.; Low-Beer, Timothy; Cookenham, Tres; Lanzer, Kathleen G.; Bernacki, Derek T.; Johnson, Lawrence L.; Schneck, Amanda A.; Ross, Corinna N.; Tardif, Suzette D.; Layne-Colon, Donna; Mdaki, Stephanie Davis; Dick, Edward J.; Chuba, Colin; González, Olga; Brasky, Kathleen M.; Dutton, John; Rutherford, Julienne N.; Coffey, Lark L.; Singapuri, Anil; Martín, Claudia Sánchez San; Chiu, Charles Y.; Thomas, Stephen J.; Modjarrad, Kayvon; Blackman, Marcia A.

doi:10.1038/s41541-021-00426-0

Cited by 18 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study conducted on the conferred maternal-fetal immune protection in mice against the Zika virus upon receipt of adenovirus vector-based vaccines concluded that adenovirus vaccines offer robust protection against the Zika virus in pregnant mice. The vaccine-elicited antibodies provide neonatal protection as well [ 31 , 35 ]. Although this study does not serve as a human vaccination precedent, it is still an important conclusion in identifying the potential benefits of adenovirus vaccinations against COVID-19 in pregnant women.…”

Section: Precedent For Covid-19 Vaccination In Pregnancymentioning

confidence: 99%

Impact of COVID-19 Vaccination on Pregnant Women

et al. 2023

View full text Add to dashboard Cite

In light of the COVID-19 pandemic, researchers across the world hastened to develop vaccines that would aid in bolstering herd immunity. Utilizing mRNA coding and viral vector technology, the currently approved vaccines were required to undergo extensive testing to confirm their safety for mass usage in the general population. However, clinical trials failed to test the safety and efficacy of the COVID-19 vaccines in groups with weakened immune systems, especially pregnant women. Lack of information on the effects of vaccinations in pregnancy and the safety of fetuses are among the topmost reasons preventing pregnant women from receiving immunization. Thus, the lack of data examining the effects of COVID-19 vaccinations on pregnant women must be addressed. This review focused on the safety and efficacy of the approved COVID-19 vaccinations in pregnancy and their impact on both maternal and fetal immune responses. For that, we took the approach of combined systematic review/meta-analysis and compiled the available data from the original literature from PubMed, Web of Science, EMBASE and Medline databases. All articles analyzed presented no adverse effects of vaccination in pregnancy, with varying conclusions on the degree of effectiveness. The majority of the findings described robust immune responses in vaccinated pregnant women, successful transplacental antibody transfer, and implications for neonatal immunity. Hence, findings from the cumulative data available can be helpful in achieving COVID-19 herd immunization, including pregnant women.

show abstract

Section: Precedent For Covid-19 Vaccination In Pregnancymentioning

confidence: 99%

Impact of COVID-19 Vaccination on Pregnant Women

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The PCR conditions were optimized using 1 μg of total RNA per reaction. Viral RNA copies were interpolated against standard curves prepared by diluting RNA from uninfected tissue spiked with a known copy number of ZIKV genomic RNA (NR-50244) obtained from BEI Resources (Manassas, VA) as described previously ( 51 ). As described previously ( 47 ), the limit of detection was defined as the cycle of threshold ( C t ) equal to 37, and the limit of quantitation was defined as a C t value of ≤35 with 100% positivity of PCR runs.…”

Section: Methodsmentioning

confidence: 99%

Impact of prior dengue virus infection on Zika virus infection during pregnancy in marmosets

et al. 2023

View full text Add to dashboard Cite

Zika virus (ZIKV) infection during pregnancy causes severe developmental defects in newborns, termed congenital Zika syndrome (CZS). Factors contributing to a surge in ZIKV-associated CZS are poorly understood. One possibility is that ZIKV may exploit the antibody-dependent enhancement of infection mechanism, mediated by cross-reactive antibodies from prior dengue virus (DENV) infection, which may exacerbate ZIKV infection during pregnancy. In this study, we investigated the impact of prior DENV infection or no DENV infection on ZIKV pathogenesis during pregnancy in a total of four female common marmosets with five or six fetuses per group. The results showed that negative-sense viral RNA copies increased in the placental and fetal tissues of DENV-immune dams but not in DENV-naïve dams. In addition, viral proteins were prevalent in endothelial cells, macrophages, and neonatal Fc receptor–expressing cells in the placental trabeculae and in neuronal cells in the brains of fetuses from DENV-immune dams. DENV-immune marmosets maintained high titers of cross-reactive ZIKV-binding antibodies that were poorly neutralizing, raising the possibility that these antibodies might be involved in the exacerbation of ZIKV infection. These findings need to be verified in a larger study, and the mechanism involved in the exacerbation of ZIKV infection in DENV-immune marmosets needs further investigation. However, the results suggest a potential negative impact of preexisting DENV immunity on subsequent ZIKV infection during pregnancy in vivo.

show abstract

“…Moreover, in mice, there was a positive correlation between fetal protection and the presence of neutralizing antibodies. Additionally, in marmoset monkeys, this vaccine was effective at preventing the vertical transmission of ZIKV (Kim et al 2022 ). Han et al tested the immunogenicity and safety of the TAK-426 vaccine in healthy people who were either flavivirus naive or flavivirus primed.…”

Section: Inactivated Vaccinesmentioning

confidence: 99%

A review on Zika vaccine development

Peng,

Yang,

et al. 2024

Pathogens and Disease

View full text Add to dashboard Cite

Zika virus (ZIKV), which belongs to the Flavivirus family, is mainly transmitted via the bite of Aedes mosquitoes. In newborns, ZIKV infection can cause severe symptoms such as microcephaly, while in adults, it can lead to Guillain‒Barré syndrome (GBS). Due to the lack of specific therapeutic methods against ZIKV, the development of a safe and effective vaccine is extremely important. Several potential ZIKV vaccines, such as live attenuated, inactivated, nucleic acid, viral vector, and recombinant subunit vaccines, have demonstrated promising outcomes in clinical trials involving human participants. Therefore, in this review, the recent developmental progress, advantages and disadvantages of these five vaccine types are examined, and practical recommendations for future development are provided.

show abstract

Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets

Cited by 18 publications

References 43 publications

Impact of COVID-19 Vaccination on Pregnant Women

Impact of COVID-19 Vaccination on Pregnant Women

Impact of prior dengue virus infection on Zika virus infection during pregnancy in marmosets

A review on Zika vaccine development

Contact Info

Product

Resources

About